[
    [
        {
            "time": "2020-10-09",
            "original_text": "President Trump getting Regeneron treatment is 'wrong and unethical': Dr. Ezekiel Emanuel",
            "features": {
                "keywords": [
                    "Trump",
                    "Regeneron",
                    "treatment",
                    "unethical"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "President Trump getting Regeneron treatment is 'wrong and unethical': Dr. Ezekiel Emanuel",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-09",
            "original_text": "Coronavirus Latest: Friday, October 9",
            "features": {
                "keywords": [
                    "Coronavirus",
                    "Latest"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Coronavirus Latest: Friday, October 9",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-10-09",
            "original_text": "Top Analyst Reports for Mastercard, JPMorgan & Eli Lilly",
            "features": {
                "keywords": [
                    "Mastercard",
                    "JPMorgan",
                    "Eli Lilly",
                    "Analyst Reports"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Top Analyst Reports for Mastercard, JPMorgan & Eli Lilly",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-09",
            "original_text": "Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs",
            "features": {
                "keywords": [
                    "LLY",
                    "AZN",
                    "PFE",
                    "GSK",
                    "Coronavirus",
                    "Progress"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-10-09",
            "original_text": "Eli Lily: Intriguing COVID-19 Story, but Questions Remain",
            "features": {
                "keywords": [
                    "Eli Lily",
                    "COVID-19",
                    "Questions"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lily: Intriguing COVID-19 Story, but Questions Remain",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-10-09",
            "original_text": "HHS expects over 1 mln antibody doses from Regeneron, Lilly in 2020",
            "features": {
                "keywords": [
                    "HHS",
                    "Regeneron",
                    "Lilly",
                    "antibody",
                    "doses"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "HHS expects over 1 mln antibody doses from Regeneron, Lilly in 2020",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-09",
            "original_text": "Should You Invest in Regeneron, Lilly, or Gilead?",
            "features": {
                "keywords": [
                    "Regeneron",
                    "Lilly",
                    "Gilead",
                    "Invest"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Should You Invest in Regeneron, Lilly, or Gilead?",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-10-09",
            "original_text": "Need More Proof That Gilead’s Treatment Helps Covid Patients? You Just Got It.",
            "features": {
                "keywords": [
                    "Gilead",
                    "Treatment",
                    "Covid",
                    "Proof"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Need More Proof That Gilead’s Treatment Helps Covid Patients? You Just Got It.",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-10-09",
            "original_text": "Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment",
            "features": {
                "keywords": [
                    "Lilly",
                    "OVERCOME",
                    "Study",
                    "Migraine",
                    "Improvement",
                    "CGRP"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]